Clinical trials: Nab-paclitaxel
Triple-Negative Breast Cancer
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)
The study is being conducted to evaluate the efficacy, safety of camrelizumab in combination with nab-paclitaxel and famitinib in Patients with unresectable locally advanced or metastatic immunomodulatory triple negative breast…
- Trial name
- NCT04129996
- Testing
- camrelizumab in combination with nab-paclitaxel and famitinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Fudan University
Valid MeSH Conditions
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, multicenter, randomized, open-label, umbrella superiority clinical trial for patients with advanced metastatic esophageal squamous cell carcinoma who have not received prior anti-tumor treatment.
- Trial name
- NCT07709533
- Testing
- Paclitaxel + Cisplatin (TP regimen) plus PD-1 inhibitor
- Where
- China
- Volunteers
- 347 people
- Sponsor
- Sun Yat-sen University
Metastatic Non-small Cell Lung Cancer
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)
This study is to assess the pharmacokinetics (PK) and safety of SC pembrolizumab formulated with berahyaluronidase alfa (MK-3475A) versus (vs) intravenous (IV) pembrolizumab (MK-3475), administered with chemotherapy in first line…
- Trial name
- NCT05722015
- Testing
- Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin
- Where
- 110 sites in United States, Argentina and 14 more
- Volunteers
- 377 people
- Sponsor
- Merck Sharp & Dohme LLC
Small Cell Lung Cancer (SCLC)
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer
The purpose of this research study is to see if Abraxane and Gemcitabine given together will be effective in treating small cell cancer that has progressed after one line of treatment.
- Trial name
- NCT02769832
- Testing
- Nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Muhammad Furqan
Advanced Solid Tumor, PIK3CA Mutation
Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations
This study will evaluate the feasibility of optimizing the safety and tolerability of serabelisib (an investigational PI3K inhibitor) when combined with an ISD and with or without nab-paclitaxel with a goal of reducing side…
- Conditions
- Advanced Solid Tumor, PIK3CA Mutation, PTEN Loss of Function Mutation
- Trial name
- NCT05300048
- Testing
- Serabelisib, Insulin Suppressing Diet, Nab paclitaxel
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Faeth Therapeutics
Non-small Cell Lung Cancer
Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer
This is a randomized, multicenter, open, controlled phase III trial. 388 subjects with stage IIIB who were not eligible for radical surgery or radiotherapy, stage IV or recurrent squamous cell NSCLC were enrolled in this study…
- Trial name
- NCT03262948
- Testing
- nab-paclitaxel, Paclitaxel, Carboplatin
- Volunteers
- 388 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Pancreatic Cancer
Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer
In the list of cancer mortality by type of cancer pancreatic cancer ranks 4th in USA and the 6th in Europe. The estimated figures for 2010 in the USA were 42,000 new cases and 36,000 deaths from pancreatic cancer.
- Trial name
- FRAGANCE (NCT02382263)
- Testing
- Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4, Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4, Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4
- Where
- 15 sites in Spain
- Volunteers
- 224 people
- Sponsor
- PH Research, S.L.
Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
Background: For patients with resectable stage III-N2b non-small cell lung cancer (NSCLC), optimal perioperative treatment strategies remain an area of active investigation.
- Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
- Trial name
- NCT07538193
- Testing
- Iparomlimab and Tuvonralimab combined with Platinum-Based Chemotherapy (Pemetrexed/Carboplatin for Non-squamous; Nab-paclitaxel/Carboplatin for Squamous)
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Tang-Du Hospital
Breast Cancer
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
This study evaluates HER2-PET/CT-guided dynamic optimization of neoadjuvant therapy in patients with early-stage HER2-positive breast cancer.
- Trial name
- NCT07527806
- Testing
- Trastuzumab (Herceptin), Pertuzumab, Combination product: Trastuzumab + Pertuzumab
- Volunteers
- 156 people
- Sponsor
- Peking University Cancer Hospital & Institute
Gastric Cancer
Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.
- Trial name
- NCT05410847
- Testing
- Camrelizumab Nab-Paclitaxel S-1
- Volunteers
- 30 people
- Sponsor
- Hebei Medical University
Non Small Cell Lung Cancer
Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer
platinum-based albumin-bound paclitaxel regimen in advanced non-small cell lung cancer (NSCLC) especially in lung squamous cell carcinoma has a better tumor response rate and safety than solvent-based paclitaxel.However, the…
- Trial name
- NCT02016209
- Testing
- nanoparticle albumin-bound paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang University
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT04115163
- Testing
- Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Anne Noonan
Advanced Solid Tumor
Study of SRF617 in Patients With Advanced Solid Tumors
A Phase 1, first-in-human, monotherapy and combination dose escalation and expansion study of SRF617.
- Trial name
- NCT04336098
- Testing
- SRF617, Gemcitabine, Albumin-Bound Paclitaxel
- Where
- 10 sites in United States, Canada
- Volunteers
- 85 people
- Sponsor
- Coherus Oncology, Inc.
Pancreatic Adenocarcinoma
Gemcitabine & Nab-Paclitaxel in Pancreatic Adenocarcinoma With Positive Peritoneal Cytology
Using gemcitabine and nab-paclitaxel, the investigators hope to establish the differential ability of local and cytologically positive disease to respond to this regimen, and in particular, the frequency of cytologic conversion…
- Trial name
- NCT03703089
- Testing
- Gemcitabine, nab-paclitaxel
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Benaroya Research Institute
Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
This phase II trial tests how well gemcitabine, cisplatin and nab-paclitaxel given before surgery (neoadjuvant) works in treating patients with pancreatic cancer that can be removed by surgery (resectable) or that is borderline…
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8
- Trial name
- NCT06423326
- Testing
- Biopsy, Biospecimen Collection, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Georgetown University
Recurrent Pancreatic Cancer
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer
- Trial name
- NCT04902261
- Testing
- Tislelizumab, Nab paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Changhai Hospital
Gastric Cancer, Second-line Therapy
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2)…
- Trial name
- NCT07320586
- Testing
- Camrelizumab, Nab paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shandong Tumor Hospital
Biliary Tract Neoplasms
An Open-label, Single-arm, Multicenter Exploratory Study of Adebrelimab Combined With Gemcitabine and Albumin-bound Paclitaxel as First-line Treatment for Biliary Tract Malignancies
The purpose of this clinical trial is to evaluate the safety and effectiveness of a new combination therapy for patients with biliary tract cancer that cannot be removed by surgery.
- Trial name
- NCT07668453
- Testing
- Adebrelimab, gemcitabine, Albumin-Bound Paclitaxel /nab-Paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable
Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma
This study is a single arm phase ll trial including 30 patients with T2N2-3M0、T3-4N0-3M0 (lll-V) head and neck squamous cell carcinoma (HNSCC) eligible forresection, who receive neo-adjvuant Cadonilimab combined with cisplatin…
- Trial name
- NCCCNRHNSCC (NCT06023875)
- Testing
- Cadonilimab, Docetaxel, Cisplatin
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Xuekui Liu
Triple Negative Breast Cancer
Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer
The primary scientific question of interest of this study is whether the combination of ociperlimab, tislelizumab and chemotherapy improves progression-free survival (PFS) compared to the combination of placebo, pembrolizumab and…
- Trial name
- AdvanTIG-211 (NCT05809895)
- Testing
- Ociperlimab, Tislelizumab, Paclitaxel
- Sponsor
- Novartis Pharmaceuticals